N-(2-呋喃基甲基)-1-(苯甲基)-1H-苯并咪唑-2-胺 | 831234-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: N-(2-呋喃基甲基)-1-(苯甲基)-1H-苯并咪唑-2-胺
• 英文名称: 1-benzyl-N-(furan-2-ylmethyl)-1H-benzo[d]imidazol-2-amine
• 英文别名: 1-benzyl-N-(furan-2-ylmethyl)-1H-benzimidazol-2-amine；1-benzyl-N-(furan-2-ylmethyl)benzimidazol-2-amine
• CAS: 831234-13-0
• 化学式: C₁₉H₁₇N₃O
• mdl: MFCD06609959
• 分子量: 303.363
• InChiKey: OECUWHDVQIITIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  43
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为产物：
  描述：

  2-氯苯并咪唑 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.5h， 生成 N-(2-呋喃基甲基)-1-(苯甲基)-1H-苯并咪唑-2-胺
  参考文献：
  名称：

  苯并咪唑支架作为 TRPC5 抑制剂的进一步探索：1-烷基-2-(pyrrolidin-1-yl)-1H-苯并[d]咪唑作为有效和选择性抑制剂的鉴定

  摘要：

  有潜力的抑制剂！原始命中化合物AC1903, 1的药物化学优化导致下一代瞬时受体电位阳离子通道 5 (TRPC5) 抑制剂16 f的形成。我们在体外和体内药代动力学试验以及其他选择性试验中分析了这种化合物。

  DOI：

  10.1002/cmdc.202200151

文献信息

• Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903
  作者：Swagat H. Sharma、Juan Lorenzo Pablo、Monica Suarez Montesinos、Anna Greka、Corey R. Hopkins

  DOI：10.1016/j.bmcl.2018.12.007

  日期：2019.1

  The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.
• TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY
  申请人：UNIVERSITY OF LEEDS

  公开号：US20200345741A1

  公开（公告）日：2020-11-05

  Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.
• [EN] BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE<br/>[FR] TRAITEMENT À BASE DE BIOMARQUEURS DE LA GLOMÉRULOSCLÉROSE SEGMENTAIRE FOCALE ET DE LA NÉPHROPATHIE DIABÉTIQUE
  申请人：GOLDFINCH BIO INC

  公开号：WO2021067946A1

  公开（公告）日：2021-04-08

  Disclosed are compounds having structural formulas (I)-(XI), and related pharmaceutical compositions. Also disclosed are methods of selecting and treating human subjects suffering from a kidney disease, using the compounds of formulas (I)-(XI), and methods of determining the efficacy of TRPC5 inhibitor therapies using the same.